Interestingly, metformin did not have any potentiating effect when combined with PI3K inhibitor, Idelalisib, likely representing redundancy of effect on the PI3K/Akt pathway in lymphoma [33, 34]. This evidence concerns the gene AKT1 and lymphoma.